Background and Objectives: Administration of analgesic medication before su
rgery, rather than at the completion of the procedure, may reduce postopera
tive pain. Similarly, administration of multiple analgesics, with different
mechanisms of action, may provide improved postoperative pain control and
functional recovery. The purpose of our study was to compare pain scores an
d intravenous opioid consumption after outpatient anterior cruciate ligamen
t (ACL) reconstruction in patients who received a multimodal drug combinati
on (intravenous [IV] ketorolac, intra-articular morphine/ropivacaine/epinep
hrine, and femoral nerve block with ropivacaine) either before surgery or i
mmediately at the completion of the surgical procedure.
Methods: Forty patients presenting for same-day arthroscopic ACL repair usi
ng a semitendinosis tendon graft were included in this study. The patients
were randomized to receive the following drugs either 15 minutes before ski
n incision or immediately after skin closure: (1) Ketorolac 30 mg IV. (2) I
ntra-articular injection of 20 mt ropivacaine 0.25% + morphine 2 mg and epi
nephrine 1:200,000. (3) Femoral nerve block with 20 mt ropivacaine 0.25%. V
erbal pain scores were obtained in the postanesthesia care unit (PACU) and
on postoperative days 1, 3, and 7. TY patient controlled analgesia (PCA) mo
rphine consumption in the PACU was also recorded.
Results: Verbal pain rating scores were lower in group I (preemptive) for 2
.0 hours after arrival in the PACU. There was no difference between groups
in pain scores on postoperative days 1, 3, and 7. Mean TV PCA morphine cons
umption in the PACU was lower in group I (6.4 mg) versus group II (12.3 mg)
, P < .05.
Conclusion: Preemptive, multimodal administration of our 3-component analge
sic drug combination resulted in lower pain scores during the initial stay
in the PACU unit and lower consumption of IV PCA morphine in the PACU. Howe
ver, pain scores were similar in both groups on postoperative days 1, 3, an
d 7; thus, there was no measurable long-term advantage associated with pree
mptive multimodal drug administration.